MOTS-c side effects have never been characterized in a completed human trial. What the CB4211 analog study, rodent work, and uncontrolled self-report actually show — and where the data stops.
Most compounds get a side-effect page because trials produced an adverse-event table. MOTS-c has no such table. No completed, published human trial of MOTS-c itself exists, which means its tolerability profile in people is not "mild" or "favourable" — it is undetermined. What follows is the honest inventory: one human dataset from a modified analog, a body of rodent work never designed as toxicology, a pile of uncontrolled self-report, and a set of mechanistic questions nobody has answered.
CohBar, the biotech founded by MOTS-c co-discoverer Pinchas Cohen, took a modified MOTS-c analog called CB4211 into a Phase 1a/1b trial for NASH and obesity. That program is the entire human record, and it is worth reading closely for two reasons.
The one clear safety signal was local, not systemic. In November 2018 CohBar temporarily suspended the Phase 1a dose-escalation stage to address injection-site reactions the company described as mild but unexpectedly persistent — generally painless bumps palpable under the skin, which CohBar attributed to a portion of the administered dose remaining localized in tissue at the injection site. The trial resumed in May 2019 after discussions with the FDA.
Systemically, the doses tested were tolerated. Topline Phase 1b results announced in August 2021 covered a randomized, double-blind, placebo-controlled evaluation of 25 mg given once daily by subcutaneous injection for four weeks in 20 obese subjects with non-alcoholic fatty liver disease. The study met its primary endpoint: CB4211 appeared safe and well tolerated, with no serious adverse events reported.
Two caveats do most of the work here. First, CB4211 is an improved analog — a different molecule with different formulation, stability, and residence-time properties than the native 16-amino-acid sequence. Its tolerability is not transferable to MOTS-c by assumption. Second, the program did not advance: CohBar subsequently suspended IND-enabling work, citing formulation problems rather than a safety finding. A four-week study in twenty people, of a related compound, is not a foundation for claims about a peptide's long-term risk.
Preclinical MOTS-c studies — beginning with Lee and colleagues in Cell Metabolism (2015), continuing through the aged-mouse physical-capacity work — have not reported overt toxicity or organ damage at the doses used. That is genuinely reassuring as far as it goes, and it does not go far.
Those experiments were designed to test metabolic and functional endpoints, not to characterize toxicity. They generally lack the elements that make a study capable of finding harm: dedicated high-dose toxicology arms, systematic histopathology, immunogenicity assessment, reproductive and carcinogenicity endpoints, and exposure durations long enough for slow effects to appear. "No toxicity reported" in a study not built to detect toxicity is a weak negative. The distinction matters more here than usual, because MOTS-c is proposed to act on AMPK and the folate–methionine cycle — broad, pleiotropic regulatory nodes touching energy metabolism, autophagy, and one-carbon metabolism upstream of epigenetic regulation. Systems that broad are exactly where long-latency effects would hide. Our MOTS-c research overview covers that mechanism in detail.
USADA's public resource on MOTS-c documents effects reported among people who describe buying the peptide online: increased heart rate or palpitations, injection-site irritation, insomnia, local or generalized immune reactions, and fever.
Treat that list as a list of hypotheses to investigate, not findings. Uncontrolled self-report carries no placebo arm, no verification that the material was MOTS-c, no purity or sterility data, no dose confirmation, and no way to separate the peptide's effects from a reconstitution solvent, a contaminant, an endotoxin load, or a concurrent compound. Fever and generalized immune reactions in particular are as consistent with material-quality failures as with pharmacology. That ambiguity is unresolvable from anecdote — which is the point.
Three plausible concerns follow from the mechanism rather than from any observed event, and each is unresolved:
Separately, MOTS-c is prohibited at all times under the WADA Prohibited List as an AMPK activator (S4, metabolic modulators), and was named explicitly on the 2025 List. For tested athletes, that is a categorical bar independent of any safety question, and a therapeutic use exemption is not realistically obtainable for a compound with no approved indication.
Is MOTS-c considered safe? There is no basis to call it safe or unsafe in humans. No completed human trial of MOTS-c has been published; the only clinical data covers a modified analog, CB4211, over four weeks in twenty subjects. Absence of reported harm in a small, short study of a different molecule is not a safety profile.
What was the injection-site problem in the CB4211 trial? CohBar suspended the Phase 1a stage in November 2018 over mild but persistent injection-site reactions — painless bumps under the skin, attributed to drug remaining localized at the site. The trial resumed in May 2019 after FDA discussions.
Does MOTS-c cause low blood sugar? No human hypoglycemia data exists. The concern is mechanistic: a compound that increases insulin sensitivity and glucose uptake would be expected to interact additively with glucose-lowering drugs. That expectation has not been tested clinically in either direction.
Why do rodent studies report no toxicity? Because they were designed to measure metabolic and performance endpoints, not to detect harm. They lack high-dose toxicology arms, systematic histopathology, and long exposure durations. See our MOTS-c dosage notes for what those studies actually administered.
Is MOTS-c banned in sport? Yes. It is prohibited at all times under WADA's S4.4.1 category for AMPK activators, and appears by name on the 2025 Prohibited List.
